Solana (HSDT) Financials

Helius Medical Technologies (NASDAQ:HSDT) showed a dramatic improvement in reported earnings in Q1 2026 compared with the prior year, but the broader multi-year trend remains highly volatile and financially fragile. Revenue in Q1 2026 rose to $3.6 million, up sharply from $0.7 million in Q3 2025 and well above the company’s 2024 quarterly levels, but operating costs and especially other operating expenses still overwhelmed gross profit. The result was a net loss of $99.8 million for Q1 2026, driven in large part by a very large $97.9 million line item in other operating expenses.

From a balance sheet perspective, HSDT ended Q1 2026 with $4.4 million in cash and $200.7 million in total assets, compared with $475.9 million in assets in Q3 2025. That decline was mainly tied to a much smaller asset base after a major reset in the company’s financial structure. The company also reported $2.8 million in total liabilities and $197.9 million in equity, but retained earnings remain deeply negative at -$312.4 million, underscoring the long history of losses.

Cash flow remains a key concern. In Q1 2026, HSDT used $4.8 million in operating cash and ended the quarter with a $2.9 million decline in cash and equivalents. That said, the latest quarter was better than the much larger cash burn seen in some prior periods, and the company generated $5.5 million from investing activities, which helped offset part of the operating outflow. Still, the business is not yet producing sustained operating cash flow.

• Revenue improved sharply year over year in Q1 2026 to $3.6 million, a meaningful increase from prior quarters.
• Gross profit was positive at $3.4 million in Q1 2026, showing the core revenue line can cover direct costs.
• Cash and equivalents of $4.4 million provide some near-term liquidity.
• Total liabilities were low at $2.8 million in Q1 2026, reflecting a lighter near-term debt burden than in prior quarters.
• Operating cash burn narrowed to a $4.8 million outflow in Q1 2026, better than some earlier periods but still negative.
• Balance sheet structure changed significantly versus 2025, making period-to-period comparisons less straightforward.
• Share count has been highly inconsistent across periods, suggesting major dilution or restructuring effects.
• Net loss remained very large at $99.8 million in Q1 2026.
• Other operating expenses were exceptionally high at $97.9 million, which crushed profitability.
• Retained earnings are deeply negative, indicating a long track record of cumulative losses.

Looking back over the last four years, HSDT’s financial profile has been inconsistent and heavily dependent on non-operating items, equity transactions, and large swings in expense recognition. The most notable trend is that revenue remains small relative to expenses, and the company has not yet shown a durable path to profitability. Investors should focus on whether future quarters can sustain higher revenue without another surge in other operating costs.

Bottom line: HSDT’s latest quarter shows better sales traction and positive gross profit, but the company still has a long way to go before its financials look stable. For retail investors, the stock remains a high-risk turnaround story with a weak earnings profile, limited cash generation, and significant volatility in reported results.